Concern over Avandia Liability Grows

Financial giant, UBS is weighing the potential costs of GlaxoSmithKline Avandia drug in light of the growing concern of its dangers. Over 13,000 lawsuits have already been filed concerning the diabetes drug and Glaxo’s expected liability ranges from $1-$6 billion dollars.

Avandia has had a long and sordid history yet despite well supported claims that the drug greatly increases the risk for heart attack, it remains on the market.

Just one week ago, the U.S. Senate Finance Committee was highly critical of the drug in a recent report. The report criticized Glaxo’s handling of heart risk associated with the drug, Avandia, claiming that Glaxo minimized safety risks and withheld vital date from the FDA. Avandia is linked with 83,000 heart attacks in a little over eight years. The FDA added a warning about heart attacks to the prescription drug in 2007.

A group of Harvard researchers recently offered a study of 26,375 diabetes patients between the years of 2000 and 2006. They found that diabetes patients taking Avandia had twice as much risk for heart attack as patients taking other diabetes medications. Twice as much! And for those that fear such numbers might be skewed, consider that Glaxo sponsored its own study which showed that Avandia users had a 35-41% heightened risk for heart attack.

This is compelling evidence that Avandia does increase the risk of heart attack. Some early liability trials against Glaxo are set for July.


If a loved one has suffered, or died from, a heart attack while taking the prescription drug, Avandia, contact our office right away for a free initial consultation.